Management of Metastatic Disease

Understanding Metastasis - Mets 101: Seed & Soil

• Metastasis: Spread of malignant cells from primary tumor to form secondary tumors at distant, non-contiguous sites.
• Seed & Soil Hypothesis (Paget, 1889):
  • "Seed": Circulating Tumor Cells (CTCs) with metastatic potential.
  • "Soil": Favorable distant organ microenvironment (e.g., specific growth factors, chemokines).
  • Explains organotropism: non-random, site-specific metastasis.
• Metastatic Cascade:
  • Local invasion → Intravasation → Survival in circulation → Extravasation → Micrometastasis → Angiogenesis → Colonization.

⭐ Common metastatic sites (fertile "soil"): Lung, Liver, Bone, Brain. (📌 LLBB: Love Large Beer Bottles).

Diagnosing & Staging Metastases - Scan, Scope, Stage!

• Scan (Imaging Workup):
  • CECT (Chest, Abdomen, Pelvis): Baseline.
  • MRI: Brain, liver, bone specifics.
  • PET-CT: Whole-body survey for occult disease, response assessment.
    • 📌 Positive Emission Tomography Can Tell all!
• Scope & Biopsy (Confirmation):
  • Image-guided or endoscopic biopsy of suspicious lesions.
  • Histopathology: Confirms metastasis, identifies primary if unknown.
  • Molecular markers (e.g., ER, HER2, PD-L1): Guides targeted therapy.
• Stage (Assessment):
  • AJCC TNM Staging (8th ed.): Defines M1 (metastatic) disease.
  • Performance Status (ECOG/Karnofsky): Guides treatment feasibility.

⭐ PET-CT is superior to conventional imaging for detecting distant metastases in many cancers, altering management in up to 20-30% of cases.

Surgical Management of Metastases - Cut the Clones!

Surgical removal of metastases (metastasectomy) aims for cure or prolonged survival in selected patients with oligometastatic disease.

• Indications for Metastasectomy:

  • Primary tumor controlled or controllable.
  • Limited number and sites of metastases (oligometastases).
  • Patient medically fit for major surgery.
  • No effective alternative systemic therapy or progression despite it.
  • Favorable tumor biology (e.g., long disease-free interval).

• Patient Selection:

  • Good performance status (ECOG 0-1).
  • Adequate organ reserve.
  • Resectability of all known disease (aim for R0).

• Common Sites & Considerations:

  • Liver: Most common for CRC; aim for ≥1 cm margin.
  • Lung: CRC, sarcoma, RCC; wedge, segmentectomy, or lobectomy.
  • Brain: Solitary, accessible lesions; often with radiotherapy.
  • Adrenal: Isolated metastasis, e.g., from lung cancer.

• Core Principles:

  • Achieve R0 resection (microscopically negative margins).
  • Preserve maximal organ function.
  • Repeat metastasectomy is feasible in select cases.

• MDT Approach: Crucial for decision-making, involving surgeons, oncologists, radiologists.

⭐ For colorectal liver metastases, 5-year survival after complete R0 resection can reach 40-50% in appropriately selected patients.

Non-Surgical & Palliative Approaches - Ease & Eradicate Extras

Error: Failed to generate content for this concept group.

High‑Yield Points - ⚡ Biggest Takeaways

• Oligometastases: Limited metastatic burden potentially curable with local therapies (surgery, SBRT).
• Liver metastasectomy: Key for colorectal cancer (CRC); R0 resection is crucial.
• Lung metastasectomy: Improves survival in selected sarcomas and CRC patients.
• CRS + HIPEC: For specific peritoneal metastases (e.g., appendiceal, ovarian, mesothelioma).
• Brain metastases: Surgery/SRS for limited lesions; WBRT for multiple.
• Bone metastases: Surgery for stabilization/decompression; radiotherapy and systemic agents are vital.
• Careful patient selection and multimodal treatment are essential for optimal outcomes.